{
    "2018-01-31": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Key Update on Gilead Sciences’ ZUMA-3 Study",
                "features": {
                    "keywords": [
                        "Gilead",
                        "ZUMA-3",
                        "Study"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Array BioPharma’s ARRY-382 and ARRY-797",
                "features": {
                    "keywords": [
                        "Array BioPharma",
                        "ARRY-382",
                        "ARRY-797"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Wall Street Is More Optimistic about JNJ Stock after 4Q17 Results",
                "features": {
                    "keywords": [
                        "JNJ",
                        "4Q17",
                        "Results",
                        "Optimistic"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Momenta Up on FDA's Amendment of McPherson Compliance Status",
                "features": {
                    "keywords": [
                        "Momenta",
                        "FDA",
                        "Amendment",
                        "Compliance"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "The Best Arthritis Drug/Treatment Stocks on the Market Right Now",
                "features": {
                    "keywords": [
                        "Arthritis",
                        "Drug",
                        "Treatment",
                        "Stocks"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "What Else Could Drive Gilead’s Long-Term Growth?",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Long-Term",
                        "Growth"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "The Swiss Stock Market Finished With A Substantial Loss",
                "features": {
                    "keywords": [
                        "Swiss",
                        "Stock Market",
                        "Loss"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX",
                "features": {
                    "keywords": [
                        "Drug",
                        "Biotech",
                        "Earnings",
                        "LLY",
                        "VRTX"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}